Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
Shun Lü(Shanghai Jiao Tong University), Xiaosheng Hang(Wuxi Fourth People's Hospital), Ligang Xing(Shandong University), Gen Lin(Fujian Medical University), Jiandong Mei(Sun Yat-sen University), Jie Jiang(Xinjiang Medical University), Mingqiang Kang(Fujian Medical University), Dongliang Yu(Guangxi University), Wentao Fang(Shanghai Jiao Tong University), Wengang Zhang(Chinese PLA General Hospital), Shidong Xu(Harbin Medical University), Aihong Zhong(Peking University), Minhua Ye(Jiangxi University of Water Resources and Electric Power), Lin Yang(Alberta Health Services), Ming Zhou(Guangzhou Medical University Cancer Hospital), Haohui Fang(Anhui Provincial Hospital), Xun Zhang(Jiangsu University), Qixun Chen(Zhejiang Cancer Hospital), Nong Yang(Central South University), Kaican Cai(Nanfang Hospital), Lijie Tan(Xinjiang Medical University), Lin Wu(Materials Systems (United States)), Nan Wu(Peking University), Yunpeng Liu(Wenzhou Medical University), Peng Zhang(Tongji University), Xiaochun Zhang(Shanghai East Hospital), Jun Chen(Fourth People's Hospital of Taiyuan), Hui Tian(Johnson & Johnson (United States)), Yuping Chen(Army Medical University), Wenxiang Wang(South China Agricultural University), Changli Wang(Second Military Medical University), Guohua Yu(Weifang People's Hospital), Hong Hu(Hubei University of Medicine), Zhixiong Yang(Guangdong Medical College), Xiaohua Hu(Cincinnati Children's Hospital Medical Center), Liangming Zhu(Shanghai Jiao Tong University), Wenqun Xing(Zhengzhou University), Yu Zhang(Central South University), Jinlu Shan(Army Medical University), Xingya Li(Zhengzhou University), Haitao Ma(Soochow University), Lejie Cao(University of Science and Technology of China), Kunshou Zhu(Fujian Medical University), Guowu Wu(Meizhou City People's Hospital), Xiaohong Sun(Xinjiang Medical University), Ke‐Neng Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Zhang(University of Toronto), Qian Sun(Rutgers, The State University of New Jersey)
Cited by 359
Related Papers
Food, nutrition, physical activity, and the prevention of cancer: a global perspective
|Choice Reviews Online|2008|5.4k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k